It’s an exciting time to be involved in biotech in New Jersey. The Garden State is home to more than 3,000 establishments in the pharma, medtech and life sciences industries—and that number is poised to grow in the future, according to BioNJ, a trade group for research-based life sciences companies. Thanks to facility expansions, acquisitions, […]

Bristol-Myers Squibb Company (BMY) will relocate hundreds of workers to a new central research hub in Cambridge, Mass. which will open in 2018, the company told BioSpace Thursday, while laying off 100 workers from its discovery staff, primarily in Connecticut. “One hundred positions will be eliminated as a result of the Discovery virology research decision,” […]

Boston, Mass.-based PAREXEL International (PRXL), a contract research organization (CRO), in conjunction with its earning guidance Tuesday, also indicated it would be laying off 850 people as part of restructuring. The restructuring process is company-wide with the goal of improving productivity and efficiency, simplifying the company’s organization and streamlining decision-making. As part of the job […]

Over the last year, one of Orange County’s most prestigious companies has been through the wringer: a hostile takeover attempt, scrutiny by the national press, layoffs and an acquisition. Allergan — the Botox maker that has been in Irvine since before the city’s founding — was purchased in March by Actavis, a pharmaceutical company headquartered […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Gregory D. Perry has resigned as Chief Financial and Business Officer, effective July 3, 2015. John J. McCabe, Eleven’s Vice President of Finance and Business Operations, is promoted to assume […]

AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura. His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved […]

AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura. His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected […]

NEW YORK–(BUSINESS WIRE)–Fitbit, Inc. (NYSE:FIT) opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “FIT” after its initial public offering on the floor of the NYSE. Barclays is the Designated Market Maker for the company’s stock. James Park, CEO and Co-Founder, and Eric Friedman, CTO and Co-Founder, joined by […]

Massachusetts is once again demonstrating how important biotech and pharma companies are to the state. Of Boston Business Journal’s list of fastest-growing public companies in the state, the top nine are all life science companies—compared to seven from 2014. MassBio reported more than 900 biopharma, medical device and diagnostics companies located in Massachusetts. The top […]